- Home
- RPID vs CLLS Comparison
RPID vs CLLS Comparison
Compare RPID & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPID
- CLLS
- Stock Information
- Founded
- RPID 2006
- CLLS 1999
- Country
- RPID United States
- CLLS France
- Employees
- RPID N/A
- CLLS N/A
- Industry
- RPID Medical Specialities
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- RPID Health Care
- CLLS Health Care
- Exchange
- RPID Nasdaq
- CLLS Nasdaq
- Market Cap
- RPID 138.9M
- CLLS 143.4M
- IPO Year
- RPID 2021
- CLLS 2007
- Fundamental
- Price
- RPID $3.47
- CLLS $1.62
- Analyst Decision
- RPID Buy
- CLLS Buy
- Analyst Count
- RPID 1
- CLLS 1
- Target Price
- RPID $8.00
- CLLS $4.00
- AVG Volume (30 Days)
- RPID 80.0K
- CLLS 49.9K
- Earning Date
- RPID 08-01-2025
- CLLS 08-05-2025
- Dividend Yield
- RPID N/A
- CLLS N/A
- EPS Growth
- RPID N/A
- CLLS N/A
- EPS
- RPID N/A
- CLLS N/A
- Revenue
- RPID $29,645,000.00
- CLLS $54,747,000.00
- Revenue This Year
- RPID $18.54
- CLLS $48.52
- Revenue Next Year
- RPID $20.55
- CLLS $5.17
- P/E Ratio
- RPID N/A
- CLLS N/A
- Revenue Growth
- RPID 28.36
- CLLS 351.26
- 52 Week Low
- RPID $0.61
- CLLS $1.10
- 52 Week High
- RPID $4.04
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- RPID 52.30
- CLLS 61.29
- Support Level
- RPID $3.45
- CLLS $1.56
- Resistance Level
- RPID $3.77
- CLLS $1.49
- Average True Range (ATR)
- RPID 0.23
- CLLS 0.09
- MACD
- RPID -0.02
- CLLS 0.02
- Stochastic Oscillator
- RPID 61.04
- CLLS 86.67
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.